CoChat
Sign Up
Cited by 9

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study

Lanièce Delaunay, Charlotte, Klein, Marina B., Godin, Arnaud, Cox, Joseph, Kronfli, Nadine, Lebouché, Bertrand, Doyle, Carla, Maheu-Giroux, Mathieu·2023·International Journal of Drug Policy
DOI 10.1016/j.drugpo.2023.104026PMC PMC10080278
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drugpo.2023.104026

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 48

  1. Aspinall, 2014, Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis, International Journal of Epidemiology, 43, 235, 10.1093/ije/dyt243 · DOI · Paper page
  2. Bao, 2009, A meta-analysis of retention in methadone maintenance by dose and dosing strategy, The American Journal Of Drug And Alcohol Abuse, 35, 28, 10.1080/00952990802342899 · DOI
  3. Baggaley, 2006, Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis, AIDS (London, England), 20, 805, 10.1097/01.aids.0000218543.46963.6d · DOI
  4. Baral, 2019, The disconnect between individual-level and population-level HIV prevention benefits of antiretroviral treatment, The Lancet HIV, 6, e632, 10.1016/S2352-3018(19)30226-7 · DOI
  5. Bartlett, 2019, The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals, Liver International, 39, 2261, 10.1111/liv.14227 · DOI
  6. Blach, 2021, Impact of COVID-19 on global HCV elimination efforts, Journal of Hepatology, 74, 31, 10.1016/j.jhep.2020.07.042 · DOI
  7. Blake, 2021, Modeling hepatitis C elimination among people who inject drugs in New Hampshire, JAMA Network Open, 4, 10.1001/jamanetworkopen.2021.19092 · DOI
  8. Boily, 2009, Heterosexual risk of HIV-1 infection per sexual act: a systematic review and meta-analysis of observational studies, The Lancet Infectious Diseases, 9, 118, 10.1016/S1473-3099(09)70021-0 · DOI
  9. Cori, 2015, CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time, AIDS (London, England), 29, 2435, 10.1097/QAD.0000000000000854 · DOI
  10. Cousien, 2017, The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study, BMC Infectious Diseases, 17, 162, 10.1186/s12879-017-2256-5 · DOI
  11. Cousien, 2018, Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France, Journal of Viral Hepatitis, 25, 1197, 10.1111/jvh.12919 · DOI
  12. Fayed, 2018, In the eyes of Indigenous people in Canada: exposing the underlying colonial etiology of hepatitis C and the imperative for trauma-informed care, Canadian Liver Journal, 1, 115, 10.3138/canlivj.2018-0009 · DOI
  13. Friesen, 2021, The impact of the COVID-19 pandemic on opioid-related harm in Ontario, Science Briefs of the Ontario COVID-19 Science Advisory Table, 2, 42
  14. Grebely, 2014, The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection, Hepatology, 59, 109, 10.1002/hep.26639 · DOI
  15. Greub, 2000, Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study, The Lancet, 356, 1800, 10.1016/S0140-6736(00)03232-3 · DOI
  16. Hajarizadeh, 2018, Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: A systematic review and meta-analysis, Lancet Gastroenterology & Hepatology, 3, 754, 10.1016/S2468-1253(18)30304-2 · DOI
  17. Hayashi, 2014, Predictors of liver-related death among people who inject drugs in Vancouver, Canada: a 15-year prospective cohort study, Journal of the International AIDS Society, 17, 19296, 10.7448/IAS.17.1.19296 · DOI
  18. Hull, 2016, CIHR Canadian HIV trials network coinfection and concurrent diseases core research group: 2016 updated Canadian HIV/hepatitis C adult guidelines for management and treatment, Canadian Journal of Infectious Diseases and Medical Microbiology, 10.1155/2016/4385643 · DOI
  19. Iversen, 2019, Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia, Journal of Hepatology, 70, 33, 10.1016/j.jhep.2018.09.030 · DOI
  20. Jacka, 2020, Prevalence of injecting drug use and coverage of interventions to prevent HIV and hepatitis C virus infection among people who inject drugs in Canada, American Journal of Public Health, 110, 45, 10.2105/AJPH.2019.305379 · DOI
  21. Jit, 2011, Modelling the epidemiology of infectious diseases for decision analysis, Pharmacoeconomics, 29, 371, 10.2165/11539960-000000000-00000 · DOI
  22. Klein, 2010, Cohort profile: The Canadian HIV–hepatitis C co-infection cohort study, International Journal of Epidemiology, 39, 1162, 10.1093/ije/dyp297 · DOI
  23. Lanièce Delaunay, 2021, Trends in hepatitis C virus seroprevalence and associated risk factors among men who have sex with men in Montréal: Results from three cross-sectional studies (2005, 2009, 2018), Sexually Transmitted Infections, 97, 290, 10.1136/sextrans-2020-054464 · DOI
  24. Lanièce Delaunay, 2021, Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?, International Journal of Drug Policy, 96, 10.1016/j.drugpo.2021.103343 · DOI
  25. Lanièce Delaunay, 2022, Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada, International Journal of Drug Policy, 103, 10.1016/j.drugpo.2022.103627 · DOI
  26. Leclerc, 2014, Estimating the size of the population of persons who inject drugs in the island of Montréal, Canada, using a six-source capture–recapture model, Drug and Alcohol Dependence, 142, 174, 10.1016/j.drugalcdep.2014.06.022 · DOI
  27. MacArthur, 2012, Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis, British Medical Journal, 345, e5945, 10.1136/bmj.e5945 · DOI · Paper page
  28. McKay, 1979, A comparison of three methods for selecting values of input variables in the analysis of output from a computer code, Technometrics, 21, 239
  29. Manns, 2017, Hepatitis C virus infection, Nature reviews Disease primers, 3, 1, 10.1038/nrdp.2017.6 · DOI
  30. Marquez, 2022, Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis, PLoS One, 17, 10.1371/journal.pone.0267853 · DOI
  31. Martin, 2018, Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?, Journal of the International AIDS Society, 2, e25062, 10.1002/jia2.25062 · DOI
  32. Montain, 2016, Impact of length of injecting career on HIV incidence among people who inject drugs, Addictive Behaviors, 58, 90, 10.1016/j.addbeh.2016.02.020 · DOI
  33. Montaner, 2011, Treatment as prevention –a double hat-trick, The Lancet, 378, 208, 10.1016/S0140-6736(11)60821-0 · DOI
  34. Olafsson, 2019, Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection: results from the treatment as prevention for hepatitis C (Trap HepC) program, Journal of Hepatology, 70, e337, 10.1016/S0618-8278(19)30659-0 · DOI
  35. Ortiz-Paredes, 2022, Potential interventions to support HCV treatment uptake among HIV co-infected people in Canada: Perceptions of patients and health care providers, Canadian Liver Journal, 5, 14, 10.3138/canlivj-2021-0021 · DOI
  36. Pitcher, 2019, Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies, Journal of Theoretical Biology, 481, 194, 10.1016/j.jtbi.2018.11.013 · DOI
  37. Platt, 2017, Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs, Cochrane Database of Systematic Reviews, 9, 10.1002/14651858.CD012021.pub2 · DOI
  38. Richardson, 2014, Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations, Antiviral research, 103, 88, 10.1016/j.antiviral.2013.12.007 · DOI
  39. Rodriguez-Torres, 2012, Peginterferon alfa-2a plus Ribavirin for HIV-HCV genotype 1 coinfected patients: A randomized international trial, HIV Clinical Trials, 13, 142, 10.1310/hct1303-142 · DOI
  40. Rubin, 1987, Journal of the American Statistical Association, 82, 543
  41. Smith, 2018, Quantifying potentially infectious sharing patterns among people who inject drugs in Baltimore, USA, Epidemiology and Infection, 146, 1845, 10.1017/S0950268818002042 · DOI
  42. Smith, 2016, Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis, BMC Infectious Diseases, 16, 471, 10.1186/s12879-016-1807-5 · DOI
  43. Sulkowski, 2015, Ombitasvir, Paritaprevir co-dosed with Ritonavir, Dasabuvir, and Ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial, Journal of the American Medical Association, 313, 1223, 10.1001/jama.2015.1328 · DOI
  44. Torriani, 2004, Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients, New England Journal of Medicine, 351, 438, 10.1056/NEJMoa040842 · DOI
  45. Trickey, 2019, The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study, The Lancet. Gastroenterology & hepatology, 4, 435, 10.1016/S2468-1253(19)30085-8 · DOI
  46. Tseng, 2015, The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future, British Journal of Clinical Pharmacology, 79, 182, 10.1111/bcp.12403 · DOI
  47. Westbrook, 2014, Natural history of hepatitis C, Journal of Hepatology, 61, S58, 10.1016/j.jhep.2014.07.012 · DOI · Paper page
  48. Wilson, 2015, The cost-effectiveness of harm reduction, International Journal of Drug Policy, 26, S5, 10.1016/j.drugpo.2014.11.007 · DOI

Cited by

Sorted by citations

See all 9

Metadata

Authors
Lanièce Delaunay, C., Klein, M. B., Godin, A., Cox, J., Kronfli, N., Lebouché, B., Doyle, C., & Maheu-Giroux, M.
Venue
International Journal of Drug Policy
Publisher
Elsevier BV
Published
2023-06
Volume
116
Pages
104026
ISSN
0955-3959
DOI
10.1016/j.drugpo.2023.104026
PMC
PMC10080278
Cited by
9
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review